Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Effective management of anemia in patients on maintenance hemodialysis (MHD) is crucial, yet traditional iron status markers like ferritin and transferrin saturation (TSAT) are often confounded by inflammation. Reticulocyte hemoglobin equivalent (RET-He), a direct measure of iron incorporation into erythroid precursors, is a promising real-time indicator of functional iron availability. This study aimed to evaluate the utility of baseline and early post-treatment RET-He in predicting hemoglobin response to intravenous (IV) iron therapy in an Indian MHD population.
We conducted a prospective observational study involving 94 anemic (hemoglobin [Hb] <10 g/dL) MHD patients with functional iron deficiency (baseline RET-He <29 pg). All participants received a total of 1 gram of IV ferric carboxymaltose. RET-He was measured at baseline and at day 7 post-infusion. The primary endpoint was hematopoietic response, defined as an increase in Hb of ≥1 g/dL at 4 weeks. The predictive performance of RET-He was evaluated using receiver operating characteristic (ROC) curve analysis.
At 4 weeks, 80.9% of patients(n= 76) were classified as responders. Responders had a significantly lower mean baseline RET-He compared to non-responders (27.10 ± 0.78 pg vs. 28.27 ± 0.80 pg; p<0.001). Baseline RET-He demonstrated excellent predictive ability for subsequent Hb response, with an Area Under the ROC Curve (AUROC) of 0.882 (95% CI: 0.799-0.964). A baseline RET-He cutoff value of ≤27.8 pg predicted response with a sensitivity of 86.8% and a specificity of 77.8%. The predictive performance improved further at day 7, with an AUROC of 0.920 (95% CI: 0.857-0.983). Importantly, baseline RET-He showed no significant correlation with serum ferritin or TSAT, highlighting its value as an independent marker.
Baseline RET-He is a powerful, non-invasive predictor of hematopoietic response to IV iron in anemic MHD patients. A value of ≤27.8 pg effectively identifies patients most likely to benefit from iron therapy. Furthermore, an early change in RET-He by day 7 serves as a robust dynamic marker of therapeutic efficacy. Integrating RET-He into routine anemia management protocols can optimize iron supplementation strategies, reduce unnecessary treatment in potential non-responders, and advance a more precise approach to patient care in the dialysis setting.
